ASPIRIN AND DIPYRIDAMOLE

Post-LOE

aspirin and dipyridamole

Dr. Reddy's Laboratories

ANDAORALCAPSULE, EXTENDED RELEASE

Approved

Oct 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ASPIRIN AND DIPYRIDAMOLE (aspirin and dipyridamole) by Dr. Reddy's Laboratories is cyclooxygenase inhibitors [moa]. Approved for stroke in patients, completed ischemic stroke due to thrombosis, completed ischemic stroke due to thrombosis (). First approved in 2018.

Drug data last refreshed 18h ago

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (3)

stroke in patients completed ischemic stroke due to thrombosis

Worked on ASPIRIN AND DIPYRIDAMOLE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.